On June 11, 2026, Evaxion A/S announced new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine designed to treat acute myeloid leukemia. The company operates in the TechBio industry, specializing in the development of AI-Immunology powered vaccines.
